Cargando…
BAFF receptor antibody for mantle cell lymphoma therapy
Mantle cell lymphoma (MCL) is an aggressive form of B cell non-Hodgkin’s lymphoma and remains incurable under current treatment modalities. One of the main reasons for treatment failure is the development of drug resistance. Accumulating evidence suggests that B cell activating factor (BAFF) and BAF...
Autores principales: | Zhang, Keman, Roy, Nand K, Vicioso, Yorleny, Woo, Janghee, Beck, Rose, de Lima, Marcos, Caimi, Paolo, Feinberg, Daniel, Parameswaran, Reshmi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939563/ https://www.ncbi.nlm.nih.gov/pubmed/33747637 http://dx.doi.org/10.1080/2162402X.2021.1893501 |
Ejemplares similares
-
NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells
por: Vicioso, Yorleny, et al.
Publicado: (2021) -
Wheat Germ Agglutinin as a Potential Therapeutic Agent for Leukemia
por: Ryva, Bradley, et al.
Publicado: (2019) -
A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers
por: Wong, Derek P., et al.
Publicado: (2022) -
Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab
por: Kowalczyk-Quintas, Christine, et al.
Publicado: (2018) -
Expression of BAFF and BAFF-R in Follicular Lymphoma: Correlation with Clinicopathologic Characteristics and Survival Outcomes
por: Li, Ya-Jun, et al.
Publicado: (2012)